Page last updated: 2024-10-28

miltefosine and Emesis

miltefosine has been researched along with Emesis in 6 studies

miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.

Research Excerpts

ExcerptRelevanceReference
"The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas."9.07Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study. ( Kok, T; Krzemieniecki, K; Mouridsen, H; Poveda, A; van Glabbeke, M; van Pottelsberghe, C; Verweij, J, 1993)
"34 patients with metastatic colorectal cancer were treated with the ether lipid miltefosine (hexadecylphosphocholine)."9.07Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. ( Planting, AS; Stoter, G; Verweij, J, 1993)
"The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas."5.07Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study. ( Kok, T; Krzemieniecki, K; Mouridsen, H; Poveda, A; van Glabbeke, M; van Pottelsberghe, C; Verweij, J, 1993)
"34 patients with metastatic colorectal cancer were treated with the ether lipid miltefosine (hexadecylphosphocholine)."5.07Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. ( Planting, AS; Stoter, G; Verweij, J, 1993)
"Miltefosine is an oral medication with anti-leishmania activity and may increase the cure rates and improve compliance."2.75Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. ( Ampuero, J; Carvalho, EM; Guimarães, LH; Machado, PR; Penna, G; Rocha, AT; Schriefer, A; Sousa, RS; Talhari, A; Villasboas, L, 2010)
"Treatment with miltefosine at 100-150 mg/day for 4 weeks has promise as an effective oral treatment of visceral leishmaniasis including antimony-resistant infection."2.69Trial of oral miltefosine for visceral leishmaniasis. ( Goyal, AK; Hilgard, P; Makharia, MK; Mandal, AK; Murray, HW; Rosenkaimer, F; Sundar, S; Voss, A, 1998)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (66.67)18.2507
2000's1 (16.67)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Machado, PR1
Ampuero, J1
Guimarães, LH1
Villasboas, L1
Rocha, AT1
Schriefer, A1
Sousa, RS1
Talhari, A1
Penna, G1
Carvalho, EM1
Stekar, J1
Hilgard, P2
Voegeli, R1
Maurer, HR1
Engel, J1
Kutscher, B1
Nössner, G1
Schumacher, W1
Verweij, J2
Krzemieniecki, K1
Kok, T1
Poveda, A1
van Pottelsberghe, C1
van Glabbeke, M1
Mouridsen, H1
Planting, AS1
Stoter, G1
Sundar, S2
Rosenkaimer, F1
Makharia, MK1
Goyal, AK1
Mandal, AK1
Voss, A2
Murray, HW2
Makharia, A1
More, DK1
Agrawal, G1
Fischer, C1
Bachmann, P1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Clinical Trial to Assess Efficacy and Safety of Orally Administered Miltefosine in Brazilian Patients With Cutaneous Leishmaniasis Compared to the Standard Care as Active Control[NCT00600548]Phase 2180 participants (Actual)Interventional2007-07-31Completed
Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705]Phase 3437 participants (Actual)Interventional2006-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Complete Clinical Response

"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment

Interventionparticipants (Number)
Miltefosine85
Glucantime®103
Thermotherapy86

Failure

At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment

Interventionparticipants (Number)
Miltefosine34
Glucantime®14
Thermotherapy42

Recurrence

Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment

InterventionParticipants (Number)
Miltefosine3
Glucantime®4
Thermotherapy6

Trials

5 trials available for miltefosine and Emesis

ArticleYear
Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.
    PLoS neglected tropical diseases, 2010, Dec-21, Volume: 4, Issue:12

    Topics: Abdominal Pain; Administration, Oral; Adolescent; Adult; Aged; Antimony; Antiprotozoal Agents; Brazi

2010
Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Male; Middle Aged; Nausea; Phosphorylcholin

1993
Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Leuk

1993
Trial of oral miltefosine for visceral leishmaniasis.
    Lancet (London, England), 1998, Dec-05, Volume: 352, Issue:9143

    Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Drug Administration Schedule; Humans;

1998
Short-course of oral miltefosine for treatment of visceral leishmaniasis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2000, Volume: 31, Issue:4

    Topics: Administration, Oral; Adult; Antiprotozoal Agents; Diarrhea; Drug Administration Schedule; Female; H

2000

Other Studies

1 other study available for miltefosine and Emesis

ArticleYear
Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133.
    Cancer chemotherapy and pharmacology, 1993, Volume: 32, Issue:6

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Cell Differentiation; Female; Ferr

1993